Lubiprostone: Evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome

Tisha N. Lunsford, Lucinda A. Harris

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Irritable bowel syndrome (IBS) is a chronic disorder that affects primarily female patients and is thought also to afflict approximately 7%-10% of the population of the Western World. Although bowel habits may change over the course of years, patients with IBS are characterized according to their predominant bowel habit, constipation (IBS-C), diarrhea (IBS-D), or mixed type (IBS-M), and treatments are focused toward the predominant symptom. Current treatments for IBS-C have included fiber, antispasmodics, osmotic and stimulant laxatives, and the now severely limited 5-HT4 agonist tegaserod. No one agent has been universally successful inthe treatment of this bothersome syndrome and the search for new agents continues.Lubiprostone (Amitiza®), a novel compound, is a member of a new class of agents called prostones and was approved for the treatment of chronic idiopathic constipation in 2006 at a dose of 24 μg twice daily and then in 2008 for the treatment of IBS-C in women only at a dose of 8 μg twice daily. Its purported mechanism is as a type 2 chloride channel activator, but recent evidence suggests that it may also work at the cystic fibrosis transport receptor. This article will compare the newly proposed mechanism of action of this compound to the purported mechanism and review the structure, pharmacology, safety, efficacy, and tolerability of this new therapeutic option. Clinical trial data leading to the approval of this agent for the treatment of IBS-C and the gender-based understanding of IBS, as well as this agent's place among existing and emerging therapies, will be examined. harris.

Original languageEnglish (US)
Pages (from-to)361-374
Number of pages14
JournalInternational Journal of Women's Health
Volume2
Issue number1
DOIs
StatePublished - 2010

Fingerprint

Irritable Bowel Syndrome
Constipation
Therapeutics
Habits
Serotonin 5-HT4 Receptor Agonists
Parasympatholytics
Laxatives
Western World
Lubiprostone
Cystic Fibrosis
Diarrhea
Clinical Trials
Pharmacology
Safety

Keywords

  • Functional bowel disorder
  • Large intestine
  • Therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Maternity and Midwifery

Cite this

Lubiprostone : Evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. / Lunsford, Tisha N.; Harris, Lucinda A.

In: International Journal of Women's Health, Vol. 2, No. 1, 2010, p. 361-374.

Research output: Contribution to journalArticle

@article{818f0eefb33c4c10ae2da83100791cc0,
title = "Lubiprostone: Evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome",
abstract = "Irritable bowel syndrome (IBS) is a chronic disorder that affects primarily female patients and is thought also to afflict approximately 7{\%}-10{\%} of the population of the Western World. Although bowel habits may change over the course of years, patients with IBS are characterized according to their predominant bowel habit, constipation (IBS-C), diarrhea (IBS-D), or mixed type (IBS-M), and treatments are focused toward the predominant symptom. Current treatments for IBS-C have included fiber, antispasmodics, osmotic and stimulant laxatives, and the now severely limited 5-HT4 agonist tegaserod. No one agent has been universally successful inthe treatment of this bothersome syndrome and the search for new agents continues.Lubiprostone (Amitiza{\circledR}), a novel compound, is a member of a new class of agents called prostones and was approved for the treatment of chronic idiopathic constipation in 2006 at a dose of 24 μg twice daily and then in 2008 for the treatment of IBS-C in women only at a dose of 8 μg twice daily. Its purported mechanism is as a type 2 chloride channel activator, but recent evidence suggests that it may also work at the cystic fibrosis transport receptor. This article will compare the newly proposed mechanism of action of this compound to the purported mechanism and review the structure, pharmacology, safety, efficacy, and tolerability of this new therapeutic option. Clinical trial data leading to the approval of this agent for the treatment of IBS-C and the gender-based understanding of IBS, as well as this agent's place among existing and emerging therapies, will be examined. harris.",
keywords = "Functional bowel disorder, Large intestine, Therapy",
author = "Lunsford, {Tisha N.} and Harris, {Lucinda A.}",
year = "2010",
doi = "10.2147/IJWH.S4537",
language = "English (US)",
volume = "2",
pages = "361--374",
journal = "International Journal of Women's Health",
issn = "1179-1411",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Lubiprostone

T2 - Evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome

AU - Lunsford, Tisha N.

AU - Harris, Lucinda A.

PY - 2010

Y1 - 2010

N2 - Irritable bowel syndrome (IBS) is a chronic disorder that affects primarily female patients and is thought also to afflict approximately 7%-10% of the population of the Western World. Although bowel habits may change over the course of years, patients with IBS are characterized according to their predominant bowel habit, constipation (IBS-C), diarrhea (IBS-D), or mixed type (IBS-M), and treatments are focused toward the predominant symptom. Current treatments for IBS-C have included fiber, antispasmodics, osmotic and stimulant laxatives, and the now severely limited 5-HT4 agonist tegaserod. No one agent has been universally successful inthe treatment of this bothersome syndrome and the search for new agents continues.Lubiprostone (Amitiza®), a novel compound, is a member of a new class of agents called prostones and was approved for the treatment of chronic idiopathic constipation in 2006 at a dose of 24 μg twice daily and then in 2008 for the treatment of IBS-C in women only at a dose of 8 μg twice daily. Its purported mechanism is as a type 2 chloride channel activator, but recent evidence suggests that it may also work at the cystic fibrosis transport receptor. This article will compare the newly proposed mechanism of action of this compound to the purported mechanism and review the structure, pharmacology, safety, efficacy, and tolerability of this new therapeutic option. Clinical trial data leading to the approval of this agent for the treatment of IBS-C and the gender-based understanding of IBS, as well as this agent's place among existing and emerging therapies, will be examined. harris.

AB - Irritable bowel syndrome (IBS) is a chronic disorder that affects primarily female patients and is thought also to afflict approximately 7%-10% of the population of the Western World. Although bowel habits may change over the course of years, patients with IBS are characterized according to their predominant bowel habit, constipation (IBS-C), diarrhea (IBS-D), or mixed type (IBS-M), and treatments are focused toward the predominant symptom. Current treatments for IBS-C have included fiber, antispasmodics, osmotic and stimulant laxatives, and the now severely limited 5-HT4 agonist tegaserod. No one agent has been universally successful inthe treatment of this bothersome syndrome and the search for new agents continues.Lubiprostone (Amitiza®), a novel compound, is a member of a new class of agents called prostones and was approved for the treatment of chronic idiopathic constipation in 2006 at a dose of 24 μg twice daily and then in 2008 for the treatment of IBS-C in women only at a dose of 8 μg twice daily. Its purported mechanism is as a type 2 chloride channel activator, but recent evidence suggests that it may also work at the cystic fibrosis transport receptor. This article will compare the newly proposed mechanism of action of this compound to the purported mechanism and review the structure, pharmacology, safety, efficacy, and tolerability of this new therapeutic option. Clinical trial data leading to the approval of this agent for the treatment of IBS-C and the gender-based understanding of IBS, as well as this agent's place among existing and emerging therapies, will be examined. harris.

KW - Functional bowel disorder

KW - Large intestine

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=78650743393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650743393&partnerID=8YFLogxK

U2 - 10.2147/IJWH.S4537

DO - 10.2147/IJWH.S4537

M3 - Article

C2 - 21151683

AN - SCOPUS:78650743393

VL - 2

SP - 361

EP - 374

JO - International Journal of Women's Health

JF - International Journal of Women's Health

SN - 1179-1411

IS - 1

ER -